Glucocorticoid administration in athletes: Performance, metabolism and detection
| Autor: | Katia Collomp, Alexandre Arlettaz, Anne-Marie Lecoq, Cynthia Mongongu, Corinne Buisson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Clinical Biochemistry Ergogenic Effects Pharmacology Bioinformatics 01 natural sciences Biochemistry 03 medical and health sciences 0302 clinical medicine Endocrinology medicine Humans Molecular Biology Glucocorticoids Doping in Sports biology business.industry Athletes 010401 analytical chemistry Organic Chemistry 030229 sport sciences biology.organism_classification Monitoring program 0104 chemical sciences Substance Abuse Detection Physical performance Female business Administration (government) Glucocorticoid medicine.drug |
| Zdroj: | Steroids. 115 |
| ISSN: | 1878-5867 |
| Popis: | It is generally acknowledged in the sporting world that glucocorticoid (GC) use enhances physical performance. This pharmacological class is therefore banned by the World Anti-Doping Agency (WADA) in in-competition samples after systemic but not local (defined as any route other than oral, intravenous, intramuscular or rectal) administration, which thus allows athletes to use GCs for therapeutic purposes. According to the 2016 WADA list, the urine reporting level for all GCs is set at 30ng/ml to distinguish between the authorized and banned routes of administration. The actual data on the ergogenic effects of GC intake are nevertheless fairly recent, with the first study showing improved physical performance with systemic GC administration dating back only to 2007. Moreover, the studies over the last decade coupling ergogenic and metabolic investigations in humans during and after GC intake have shown discrepant results. Similarly, urine discrimination between banned and authorized GC use remains complex, but it seems likely to be improved thanks to new analytical studies and the inclusion of the authorized GC uses (local routes of administration and out-of-competition samples) in the WADA monitoring program. In this review, we first summarize the current knowledge on the ergogenic and metabolic GC effects in humans during various types of exercise. We then present the antidoping legislation and methods of analysis currently used to detect GC abuse and conclude with some practical considerations and perspectives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect